CA2584422A1 - 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists - Google Patents

1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists Download PDF

Info

Publication number
CA2584422A1
CA2584422A1 CA002584422A CA2584422A CA2584422A1 CA 2584422 A1 CA2584422 A1 CA 2584422A1 CA 002584422 A CA002584422 A CA 002584422A CA 2584422 A CA2584422 A CA 2584422A CA 2584422 A1 CA2584422 A1 CA 2584422A1
Authority
CA
Canada
Prior art keywords
pyrrolidin
mmol
compound
amine
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584422A
Other languages
English (en)
French (fr)
Inventor
Thomas Charles Britton
Veronique Dehlinger
Colin Peter Dell
Bruce Anthony Dressman
Jason Kenneth Myers
Eric Samuel Nisenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2584422A1 publication Critical patent/CA2584422A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA002584422A 2004-10-18 2005-10-13 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists Abandoned CA2584422A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61978904P 2004-10-18 2004-10-18
US60/619,789 2004-10-18
PCT/US2005/036665 WO2006044454A1 (en) 2004-10-18 2005-10-13 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists

Publications (1)

Publication Number Publication Date
CA2584422A1 true CA2584422A1 (en) 2006-04-27

Family

ID=35787981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584422A Abandoned CA2584422A1 (en) 2004-10-18 2005-10-13 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists

Country Status (12)

Country Link
US (1) US7868014B2 (enExample)
EP (1) EP1805165B1 (enExample)
JP (1) JP5188807B2 (enExample)
CN (1) CN101094846A (enExample)
AT (1) ATE452130T1 (enExample)
AU (1) AU2005295860A1 (enExample)
BR (1) BRPI0516602A (enExample)
CA (1) CA2584422A1 (enExample)
DE (1) DE602005018381D1 (enExample)
ES (1) ES2336130T3 (enExample)
MX (1) MX2007004661A (enExample)
WO (1) WO2006044454A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1757582T3 (pl) * 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
TW201022233A (en) * 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2015359352B2 (en) 2014-12-11 2020-07-02 Janssen Pharmaceutica Nv 1,2,4-triazolo(4,3-a)pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors
CN113024412A (zh) * 2021-03-23 2021-06-25 上海立科化学科技有限公司 2,4,6-三氯苯腈的制备方法
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法
CN115368283A (zh) * 2022-09-15 2022-11-22 丽水绿氟科技有限公司 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4785119A (en) 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5332817A (en) 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
WO1995029891A1 (en) * 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DK0874625T3 (da) 1996-01-22 2005-06-20 Lilly Co Eli Indanderivater til antipsykotiske præparater
AU1608397A (en) 1996-02-02 1997-08-22 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6204292B1 (en) 1997-07-18 2001-03-20 Georgetown University Bicyclic metabotropic glutamate receptor ligands
CA2297906A1 (en) 1997-07-22 1999-02-04 Bret Eugene Huff Pharmaceutical compounds
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
WO1999064396A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
WO2002091988A2 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
AU2003300021A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100803796B1 (ko) 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
CA2539335A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
PL1757582T3 (pl) * 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania

Also Published As

Publication number Publication date
JP2008516959A (ja) 2008-05-22
EP1805165A1 (en) 2007-07-11
CN101094846A (zh) 2007-12-26
BRPI0516602A (pt) 2008-09-16
WO2006044454A1 (en) 2006-04-27
DE602005018381D1 (de) 2010-01-28
AU2005295860A1 (en) 2006-04-27
US20080300266A1 (en) 2008-12-04
US7868014B2 (en) 2011-01-11
ATE452130T1 (de) 2010-01-15
ES2336130T3 (es) 2010-04-08
EP1805165B1 (en) 2009-12-16
JP5188807B2 (ja) 2013-04-24
MX2007004661A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
EP1591443B1 (en) Pyrazole derivative
CN101903372A (zh) 作为食欲肽受体拮抗剂的杂芳基衍生物
KR20150042269A (ko) N형 칼슘 채널 차단제로서의 치환된 피라졸
CN105814019A (zh) 脲衍生物、或其药理学上所容许的盐
AU2008240728B2 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP1805165B1 (en) 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mglur3 receptor antagonists
EP1912968A1 (en) Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
AU2006307930A1 (en) Piperidin-4-YL-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2766353B1 (en) 2-oxo-piperidinyl derivatives
JP2010511673A (ja) 迅速に解離するドーパミン２受容体アンタゴニストとしてのピペリジニルアミノ−ピリダジンおよびそれらの使用
CN102482259B (zh) 作为nk3受体拮抗剂的吡咯烷衍生物
AU2008240727B2 (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
JP2011522855A (ja) Ｎｋ３受容体アンタゴニストとしてのピロリジンエーテル誘導体
EP1659121A1 (en) 1,3-dihydro-2h-indol-2-one derivative
EP2243778A1 (en) Piperidine derivative
EP2212309A1 (en) Trisubstituted 1,2,4-triazoles
CN102307853A (zh) 作为nk3受体拮抗剂的吡咯烷衍生物
HK1139674A (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
HK1139678A (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
ME01208B (me) Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora
HK1139686A (en) Sulfonamide derivative

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130826